Chronic infection patients around the world are in urgent need for better treatment options. At D&D Pharma, we believe that the most effective way to combat many antibiotic-resistant infections is through the natural lytic (bacterio)phage mechanism.

We have taken on the task of developing bacteriophage-based medicinal products for the treatment of severe infections, thus combining existing state of the art and in-house R&D capabilities. We have pioneered the clinical application of extremely effective and affordable therapeutic solutions for many severely affected patients in Germany. All the while, we have continuously been in the forefront of clinical studies to establish the efficacy and safety of our products.

The Resistance phenomenon

In the past decade, an increasing number of cases has been reported where regularly prescribed antibiotic therapies have failed, leaving patients with chronic and nosocomial infections without treatment options. As early as 2000, a special WHO report on Antimicrobial Resistance has pointed to the dangerous dynamic of antibiotic-resistant bacterial infections. Today, a considerable number of patients are "living" with this dynamic. 

The phenomenon of antibiotic resistance has accelerated since 2000 and many more hospitals, clinics and patients in developed countries, including Germany, report a significant increase in dangerous, resistant pathogens, such as Staph Aureas (MRSA), Pseudomonas and others. The development of new conventional antibiotics is extremely time consuming and costly, whereas the development of resistance is relatively swift and extensive.

What does this development mean?

The development of resistant bacteria has a direct impact on affected patients. Regular antibiotic therapies have no effect and do not lead to successful treatment of symptoms. In better cases, higher dosed conventional antibiotic therapies can lead to permanent healing. Often, however, higher dosed conventional antibiotic therapies only alleviate primary symptoms temporarily. In worst cases, conventional antibiotic therapies have no effect at all, independent of dosage. 

The outcome:

1) No available therapy to treat chronic and severe hospital-acquired infections.

2) Where more radical therapies (such as high-dose conventional antibiotics) are available, significantly stronger side-effects are to be expected